Skip to content

Rafael Holdings, Inc. RFL Cumulative Cost Basis

Cumulative Cost Basis at other companies

Intel logo
IntelINTC
Johnson & Johnson logo
Johnson & JohnsonJNJ
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s cumulative cost basis?
Rafael Holdings, Inc. (RFL) reported cumulative cost basis of $2.59M in Q1 2026.
How has Rafael Holdings, Inc.'s cumulative cost basis changed year-over-year?
Rafael Holdings, Inc.'s cumulative cost basis decreased by 0.6% year-over-year, from $2.61M to $2.59M.
What is the long-term trend for Rafael Holdings, Inc.'s cumulative cost basis?
Over 4 years (2021 to 2025), Rafael Holdings, Inc.'s cumulative cost basis has grown at a -53.8% compound annual growth rate (CAGR), from $57.1M to $2.61M.